Date Title Description PDF
06 Nov 2025 On P&L The Company releases the press release related to the first nine months of 2025 financial results Download
06 Nov 2025 On P&L The Company releases the first nine months of 2025 financial results presentation Download
21 Oct 2025 On business and financial situation The Company releases the press release in relation to the announcement of the collaboration with Roche for the manufacture of a new medicine in development Download
29 Sep 2025 On corporate transactions: mergers, acquisitions and others The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) Download
29 Sep 2025 On corporate transactions: mergers, acquisitions and others ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) Download

Pages

Date Title Description PDF
12 Sep 2024 Other relevant information The Company announces the registration in the Commercial Registry of the public deed of reduction of its share capital and the new share capital figure. Download
01 Aug 2024 Other relevant information The Company has agreed to execute the share capital reduction approved by the 2024 Ordinary General Meeting to amortize treasury shares, among which those acquired in the framework of the own shares repurchase program. Download
31 Jul 2024 Liquidity and counterparty agreements Modification of securities and cash balances associated with the Liquidity Contract signed between the Company and Bestinver, S.V., S.A. Download
08 Jul 2024 Other relevant information The Company informs about the dividends payment.   Download
04 Jul 2024 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2024 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages